Lymphoma, Non-Hodgkin: all 2,043 studies
Page 17 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00717925Phase 1
- Health and Psychosocial Outcomes in Long-Term Lymphoma SurvivorsCompletedNCT00713882
- PET Study in Patients With Non-Hodgkin LymphomaCompletedNCT00712556
- CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide GeneActive, not recruitingNCT00710892Phase 1
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1
- T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLLCompletedNCT00709033Phase 1
- Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins LymphomaCompletedNCT00693602Phase 1
- Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant LymphomasCompletedNCT00685997
- Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).CompletedNCT00665314Phase 2
- Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's LymphomaTerminatedNCT00664144Phase 2
- Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLCompletedNCT00655837Phase 1
- Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's LymphomaTerminatedNCT00651443Phase 1
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
- Freiburg ZNS-NHL StudyStatus unknownNCT00647049Phase 2
- Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse LymphomCompletedNCT00646750Phase 2
- Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)CompletedNCT00644371Phase 2
- Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell LymphomaCompletedNCT00644124Phase 1
- Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaCompletedNCT00641381Phase 1
- A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00622258Phase 1
- Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's LymphomaCompletedNCT00614042Phase 1
- Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00612183Phase 2
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
- Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell LymphomaCompletedNCT00606645Phase 1
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin LymphomaCompletedNCT00598169Phase 1
- Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaCompletedNCT00596804Phase 1/2
- The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment PlanningCompletedNCT00588328Phase 1
- AIDS and Cancer Specimen Bank (ACSB)CompletedNCT00587912
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00587015Phase 1
- Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial CancersActive, not recruitingNCT00579163
- Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLWithdrawnNCT00577161Phase 3
- Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00575068Phase 1/2
- CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's LymphomaCompletedNCT00574730Not applicable
- Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's LymphomaCompletedNCT00574626Not applicable
- Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's LymphomaCompletedNCT00574509Phase 1
- Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's LymphomasCompletedNCT00572637Phase 1
- Prevention of Methotrexate Induced Nephrotoxicity and Prolonged Drug Elimination Time With 12 Hours PrehydrationCompletedNCT00570817Not applicable
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsCompletedNCT00562224Phase 1
- Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00558727Phase 1
- A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaCompletedNCT00556699Phase 1
- Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's LymphomasCompletedNCT00554164Phase 3
- Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at DiagnosisCompletedNCT00553943Phase 2
- Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT00551239Phase 3
- Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's LymphomaCompletedNCT00549185Phase 1
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedNCT00546793Phase 1/2
- MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaTerminatedNCT00543582Phase 2
- Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma CasesStatus unknownNCT00538551
- Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaTerminatedNCT00538187Phase 1
- A Phase I Study to Evaluate Safety, Tolerability in Adults With LymphomaWithdrawnNCT00538096Phase 1
- Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins LymphomaCompletedNCT00536835Phase 1
- Treatment of Localized Low Grade LymphomasCompletedNCT00536458Phase 3
- Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCTCompletedNCT00534989Not applicable
- Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00534820Not applicable
- Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's LymphomaCompletedNCT00533728Phase 1
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLTerminatedNCT00529503Phase 2
- Study Evaluating TRU-015 in B-Cell Non-Hodgkin's LymphomaTerminatedNCT00521638Phase 1
- A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin LymphomasCompletedNCT00521560Phase 2
- Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWithdrawnNCT00521261Phase 1
- A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)CompletedNCT00517049Phase 2
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell TransplantTerminatedNCT00515138Early Phase 1
- Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaCompletedNCT00511082Phase 1
- Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With LymphomaTerminatedNCT00510471Phase 2
- Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell TransplantCompletedNCT00510315
- Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent LymphomaCompletedNCT00509379Phase 2
- A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid TumorsCompletedNCT00503451Phase 1
- A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18CompletedNCT00500058Phase 1
- Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
- A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)TerminatedNCT00499239Phase 1/2
- The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins LymphomaWithdrawnNCT00498667
- Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's LymphomaCompletedNCT00491127Phase 2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHLCompletedNCT00477945Phase 1
- Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877TerminatedNCT00471367Phase 1
- Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's LymphomaStatus unknownNCT00463463Phase 3
- Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
- A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1
- CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's LymphomaTerminatedNCT00455897Phase 2
- A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaTerminatedNCT00452127Phase 1/2
- Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00443976Phase 1
- Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaCompletedNCT00440388Phase 2
- Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's LymphomaStatus unknownNCT00438581Phase 2
- Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell LymphomaCompletedNCT00435916Phase 2
- Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous TransplantCompletedNCT00434629Phase 1
- Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy.TerminatedNCT00432419Phase 1/2
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesCompletedNCT00430846Phase 1
- Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.Status unknownNCT00429065
- Safety Study of NHL With 90Y-hLL2 IgGCompletedNCT00421395Phase 1/2
- Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow CancersTerminatedNCT00421213Phase 2
- A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1
- A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2
- Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9Status unknownNCT00400907
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody TreatmentCompletedNCT00398372Not applicable
- Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaStatus unknownNCT00397800Phase 1/2
- A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT00389051Phase 1
- Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHLStatus unknownNCT00385125Phase 2
- Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-LymphomaStatus unknownNCT00384553Phase 1/2
- Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00384150Phase 3
- Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's LymphomaTerminatedNCT00383097Phase 1
- CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's LymphomaCompletedNCT00374179Phase 1
- Velcade in MALT Lymphoma PatientsCompletedNCT00373906Phase 2
- Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)Active, not recruitingNCT00368082Phase 1